Drug Trial Radar · NCT06161571
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
Nov 10, 2023
Primary completion
Mar 3, 2026
Study completion Jun 19, 2026
Sponsor
- Lead sponsor
- Akero Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
Conditions
- NASH/MASH
- NAFLD/MASLD
Interventions
EfruxiferminDrug
Administered by subcutaneous (SC) injection
PlaceboDrug
Administered by SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Extent of exposureTime frame: 52 Weeks
- Number of participants with adverse eventsTime frame: 52 Weeks
- Number of participants with adverse events by severityTime frame: 52 Weeks
- Number of participants with clinically significant changes in clinical assessmentsTime frame: 52 Weeks
Locations
211 sites in 13 countries. Site status is shown where the registry gives one.
Akero Clinical Study Site
Birmingham, Alabama
Akero Clinical Study Site
Chandler, Arizona
Akero Clinical Study Site
Flagstaff, Arizona
Akero Clinical Study Site
Peoria, Arizona
Akero Clinical Study Site
Tucson, Arizona
Akero Clinical Study Site
Tucson, Arizona
Akero Clinical Study Site
Conway, Arkansas
Akero Clinical Study Site
Jonesboro, Arkansas
Akero Clinical Study Site
Little Rock, Arkansas
Akero Clinical Study Site
North Little Rock, Arkansas
Akero Clinical Study Site
Chula Vista, California
Akero Clinical Study Site
Coronado, California
Akero Clinical Study Site
Cypress, California
Akero Clinical Study Site
Inglewood, California
Akero Clinical Study Site
La Mesa, California
Akero Clinical Study Site
Lancaster, California
Akero Clinical Study Site
Los Angeles, California
Akero Clinical Study Site
Los Angeles, California
Akero Clinical Study Site
Palm Springs, California
Akero Clinical Study Site
San Diego, California
Akero Clinical Study Site
San Diego, California
Akero Clinical Study Site
San Francisco, California
Akero Clinical Study Site
Santa Maria, California
Akero Clinical Study Site
Englewood, Colorado
Akero Clinical Study Site
Bradenton, Florida
Akero Clinical Study Site
Brandon, Florida
Akero Clinical Study Site
Fort Myers, Florida
Akero Clinical Study Site
Gainesville, Florida
Akero Clinical Study Site
Hialeah Gardens, Florida
Akero Clinical Study Site
Inverness, Florida
Akero Clinical Study Site
Jacksonville, Florida
Akero Clinical Study Site
Lady Lake, Florida
Akero Clinical Study Site
Lakewood Rch, Florida
Akero Clinical Study Site
Largo, Florida
Akero Clinical Study Site
Maitland, Florida
Akero Clinical Study Site
Miami, Florida
Akero Clinical Study Site
Miami Lakes, Florida
Akero Clinical Study Site
Naples, Florida
Akero Clinical Study Site
Ocala, Florida
Akero Clinical Study Site
Port Orange, Florida
Showing 40 of 211 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.